CSTL insider Form 4: 2,678 Castle Biosciences shares sold
Rhea-AI Filing Summary
Castle Biosciences Inc. insider trading report: A reporting person who serves as a director and as President & Chief Executive Officer of Castle Biosciences (CSTL) sold 2,678 shares of common stock on 11/18/2025 at a weighted-average price of $34.02 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2025. After this transaction, the insider directly holds 50,937 shares of common stock and also reports indirect ownership through multiple family and grantor retained annuity trusts, including 52,923 shares held by The Maetzold Descendants 2020 Trust and 44,986 shares held by the Derek Maetzold 2020 Irrevocable Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,678 | $34.02 | $91K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. This transaction was executed in multiple trades at prices ranging from $33.79 to $34.16, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
FAQ
What insider transaction did CSTL report in this Form 4?
The Form 4 reports that a Castle Biosciences (CSTL) insider who is a director and President & Chief Executive Officer sold 2,678 shares of common stock on 11/18/2025.
Was the Castle Biosciences (CSTL) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025.
What is the role of the reporting person at Castle Biosciences (CSTL)?
The reporting person is identified as a director and an officer, specifically serving as President & Chief Executive Officer of Castle Biosciences.